Abstract
Diabetic retinopathy (DR) is a significant neurovascular complication driven by abnormal angiogenesis. This study evaluated the efficacy and safety of Lanctos 75™, a proprietary standardized extract of Orthosiphon stamineus leaves (code name C5OSEW5050ESA), as a retinal-protective and anti-neovascular agent in streptozotocin-induced diabetic retinopathy in rats. The safety and neuroprotective properties of Lanctos 75™ were assessed in various in vitro and in vivo models of ischemia-induced neuronal injury. In vitro studies using RGC-5 cells showed that Lanctos 75™ significantly suppressed apoptosis, demonstrating strong cytoprotective effects. In vivo, PanOptic ophthalmoscopic imaging in diabetic rats revealed that Lanctos 75™ protected against retinal damage, inhibiting the development of microaneurysms, hemorrhages, vascular leakage, venous beading, and retinal inflammation. Fluorescence molecular tomography (FMT) imaging further confirmed its protective effect against ischemia-reperfusion injury and related inflammation. Overall, the results suggest that Lanctos 75™, with an effective dose of O. stamineus, holds promise as an adjunct therapy for diabetic retinopathy and other neovascular-related eye conditions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
